KOMO Biosciences

KOMO Biosciences is a next-generation targeted gene integration technology company driven by the power of KOMbine™, a high-efficiency, integrase technology platform which aims to unlock significant opportunities in life sciences. Our mission is to advance the frontier of genetic engineering by developing innovative, high-efficiency gene editing technologies to enable precise and scalable genetic modifications. The KOMbine™ integrease technology platform aims to empowers industries across healthcare, agriculture, and biotechnology to solve complex global challenges. KOMbine™ is a non-viral, non-nuclease genetic engineering technology platform capable of large gene insertion into pre-defined, high-expressing regions with unprecedented high efficiencies. The integrase technology platform does not induce unprotected double strand DNA breaks thereby potentially addressing limitations of current gene engineering methods with respect to off target editing, low efficiency, and inability to insert large fragments of DNA. KOMbine™ addresses four critical pain points: the need for targeted, high-efficiency and safe genome insertion, urgency for accelerated manufacturing timelines, the need for non-viral delivery of cell and gene therapies, and the need for high integration efficiency for application in ex-vivo and in-vivo cell therapy. Additionally, KOMbine enables rapid design-test cycles, antibiotic-free systems, and is capable of large, sophisticated molecular constructs to enable complex engineering. Whether you’re manufacturing antibodies, engineering cell and gene therapies, or building next-gen biologics, KOMbine™ enables targeted, efficient, and reproducible delivery of large genetic payloads. KOMbine's™ can accelerate the efforts of therapeutic developers, contract research and development manufacturing organizations, and government agencies through licensing agreements and strategic partnerships.